文献速递胸部CT

糖尿病或继发性高血糖COVID-19出院患者肺部后遗症的随访研究

Follow-up study of pulmonary sequelae in discharged COVID-19 patients with diabetes or secondary hyperglycemia.
PubMed 文献 · Eur J Radiol · 2021-10-09

该研究纳入141例COVID-19患者,分糖尿病组、继发性高血糖组和对照组,在症状出现后16天、175天和351天进行胸部CT随访。6个月时54.6%患者仍有残留肺部异常,糖尿病和高血糖组发生率显著高于对照组;住院时长>20天、LDH峰值≥317 U/L和初始CT总分>15是糖尿病或高血糖患者残留肺部异常的独立预测因素。

要点

  • 糖尿病或继发性高血糖COVID-19患者6个月残留肺部异常率高于对照组。
  • 网格影和磨玻璃影是随访中最常见的残留CT异常。
  • 住院时长>20天、LDH≥317 U/L、初始CT总分>15提示残留异常风险高。

核心结论

  • 相当比例糖尿病或继发性高血糖COVID-19存活者6个月时仍有残留肺部异常,1年随访可见持续胸部CT改变。
  • 残留肺部异常与住院时间较长、LDH峰值较高和初始CT总分较高相关。

研究设计与样本

  • 研究共纳入141例COVID-19患者,分为糖尿病组、继发性高血糖组和对照组。
  • 在症状出现后16天、175天和351天分别进行初始、6个月和12个月胸部CT随访。
  • 使用单变量和多变量逻辑回归分析识别6个月随访时残留肺部异常的独立预测因素。

关键影像表现/征象

  • 6个月随访时,77/141(54.6%)患者胸部CT仍可见异常。
  • 网格影(40/141,28.4%)和磨玻璃影(29/141,20.6%)是最常见的残留CT异常。
  • 糖尿病组和继发性高血糖组残留肺部异常发生率分别为65.4%和58.3%,显著高于对照组的36.6%(p<0.05)。
  • 12个月随访时,25例患者中13例(52.0%)胸部CT改变持续存在。

诊断标准与关键数值

  • 住院时长>20天(OR: 5.630, 95% CI: 1.394-22.744, p=0.015)是糖尿病或继发性高血糖患者残留肺部异常的独立预测因素。
  • LDH水平≥317 U/L(OR: 7.020, 95% CI: 1.032-47.743, p=0.046)是独立预测因素。
  • 初始总CT评分>15(OR: 9.919, 95% CI: 1.378-71.415, p=0.023)是独立预测因素。

临床应用与阅片要点

  • 对糖尿病或继发性高血糖的COVID-19出院患者,应关注6个月和12个月随访CT上的网格影和磨玻璃影。
  • 报告时可结合住院时长、LDH峰值和初始CT总分提示残留肺部异常风险。
  • 初始CT总分>15、LDH≥317 U/L或住院>20天的患者建议密切随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To determine chest CT changes 6 months and 12 months after the onset of coronavirus disease 2019 (COVID-19) in patients with diabetes or hyperglycemia and the risk factors for these residual lung abnormalities.

METHODS: In total, 141 COVID-19 patients were assigned to group 1 (diabetes), group 2 (secondary hyperglycemia) or group 3 (controls). Initial and six- and twelve-month follow-up computed tomography (CT) scans were performed 16 days, 175 days and 351 days after symptom onset, respectively. CT findings and clinical and peak laboratory parameters were collected and compared. Univariable and multivariable logistic regression analyses were performed to identify the independent predictors for the presence of residual lung abnormalities at the 6-month follow-up exam. Seven variables (age; the presence of acute respiratory distress syndrome; the duration of hospitalization; the peak levels of lactate dehydrogenase (LDH) and C-reactive protein; and the initial total CT score) were chosen in the final multivariable models.

RESULTS: At the six-month follow-up, abnormalities were still observed on chest CT in 77/141 (54.6%) patients. Reticular patterns (40/141, 28.4%) and ground-glass opacities (GGOs) (29/141, 20.6%) were the most common CT abnormalities on the follow-up CT scans. Patients in Groups 1 and 2 had significantly higher incidences of residual lung abnormalities than those in Group 3 (65.4% and 58.3%, respectively vs. 36.6%; p < 0.05). Twelve months after disease onset, the chest CT changes persisted in 13/25 (52.0%) patients. A duration of hospitalization > 20 days (OR: 5.630, 95% CI: 1.394-22.744, p = 0.015), an LDH level ≥ 317 U/L (OR: 7.020, 95% CI: 1.032-47.743, p = 0.046) and a total CT score > 15 (OR: 9.919, 95% CI: 1.378-71.415, p = 0.023) were independent predictors of residual pulmonary abnormalities in patients with diabetes or secondary hyperglycemia.

CONCLUSIONS: A considerable proportion of surviving COVID-19 patients with diabetes or secondary hyperglycemia had residual pulmonary abnormalities six months after disease onset, and we found evidence of persistent chest CT changes at the one-year follow-up. Residual lung abnormalities were associated with longer hospital stays, higher peak LDH levels and higher initial total CT scores.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Li Y, Han X, Huang J, et al. Follow-up study of pulmonary sequelae in discharged COVID-19 patients with diabetes or secondary hyperglycemia. Eur J Radiol. 2021. PMID: 34634534. doi:10.1016/j.ejrad.2021.109997

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。